Jasper Therapeutics, Inc. JSPR
0.61
0.02
3.39%
as of 25 Sep
- Market cap
- $19.5M
- P/E
- 0.0×
Follow JSPR
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Current Ratio |
+8 more quarters Free account |
2.59 | 2.62 | 2.26 | 1.48 |
Net Debt/EBITDA |
2.69 | 1.85 | 1.29 | 0.84 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.91 | 2.40 | 12.39 | 2.51 | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 3.81 | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow per Share |
(1.02) | (1.14) | (0.51) | (0.24) | |
Cash per Share |
3.06 | 1.50 | 0.49 | 0.27 | |
Shareholders Equity per Share |
0.70 | 0.22 | 0.12 | 0.05 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.70 | 0.22 | 0.12 | 0.05 | |
Free Cash Flow |
(17.00) | (21.87) | (14.55) | (6.84) | |
Working Capital |
33.52 | 21.45 | 11.30 | 3.73 | |
Capital Expenditures |
0.00 | 0.00 | — | 0.08 | |
Net Current Asset Value |
8.67 | 3.02 | 2.51 | 1.18 | |
| Other line items | |||||
Quick Ratio |
2.42 | 2.17 | 1.57 | 0.99 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(1.02) | (1.14) | (0.51) | (0.24) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Payables |
6.13 | 5.12 | 2.72 | 5.41 | |
Average Assets |
78.44 | 57.84 | 39.39 | 29.13 | |
Average Common Equity |
47.63 | 32.91 | 22.82 | 12.46 | |
Capex to Sales |
0.00 | 0.00 | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates